Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06747858
PHASE2

Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis

Sponsor: Arcturus Therapeutics, Inc.

View on ClinicalTrials.gov

Summary

ARCT-032-02 is a Phase 2, open-label, multicenter, multiple-ascending dose study of ARCT-032 in adults with CF who are not eligible for CFTR modulator therapy or are not taking CFTR modulators due to drug intolerance, poor response, or lack of access to modulators.

Official title: A Phase 2, Open-label, Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability and Efficacy of ARCT-032 in People With Cystic Fibrosis

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

12

Start Date

2024-12-12

Completion Date

2025-12

Last Updated

2025-10-09

Healthy Volunteers

No

Interventions

BIOLOGICAL

ARCT-032

CFTR mRNA formulated in lipid nanoparticles

Locations (11)

University of Arizona

Tucson, Arizona, United States

University of Arkansas for Medical Sciences

Little Rock, Arkansas, United States

Children's Hospital of Los Angeles

Los Angeles, California, United States

Joe DiMaggio Children's Hospital

Hollywood, Florida, United States

Central Florida Pulmonary Group

Orlando, Florida, United States

The Cystic Fibrosis Institute

Northfield, Illinois, United States

Boston Children's Hospital

Boston, Massachusetts, United States

Washington University

St Louis, Missouri, United States

Vanderbilt University

Nashville, Tennessee, United States

UT Health

San Antonio, Texas, United States

Seattle Children's Hospital

Seattle, Washington, United States